Effect of Compound Zaofan Pill on Bone Marrow MVD and VEGF of Patients with Chronic Aplastic Anemia.
- Author:
Fang-Fang YANG
1
;
Kang-Wei WANG
2
;
Qi XIANG
3
;
Shun-Qing WANG
4
Author Information
- Publication Type:Journal Article
- MeSH: Anemia, Aplastic; Bone Marrow; Cyclosporine; Humans; Vascular Endothelial Growth Factor A
- From: Journal of Experimental Hematology 2015;23(2):477-480
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the clinical efficacy of compound Zaofan pill combined with cyclosporine and androgen for treatment of patients with chronical aplastic anemia(CAA), and its effect on bone marrow microvessel density(MVD) and vascular endothelial growth factor(VEGF) of CAA patients.
METHODSA total of 76 cases of CAA were randomly divided into group 1 and group 2, among them the group 1 (38 cases) was treated with cyclosporine and androgen alone, while the group 2(38 cases) was treated with compound Zaofan pill combined with cyclosporine and androgen. Samples of 20 cases with normal bone marrow were used as controls. The clinical effects of each groups were observed, and the mean bone marrow MVD and VEGF levels were detected before and after half a year's treatment.
RESULTSThe mean bone marrow MVD and VEGF levels in CAA group before treatment were significantly lower than that in normal control group, but bone marrow MVD and VEGF levels in 2 groups significantly increased after treatment. Group 1 showed the cure and response rate of 15.8%, while group 2 showed the cure and response rate of 44.7%, there was significant difference between the two groups (P<0.05)). There was no significant difference of bone marrow MVD and VEGF expression before treatment between group 1 and group 2. After treatment, bone marrow MVD and VEGF expression of group 2 were significantly higher than pre-treatment, moreover the bone marrow MVD and VEGF expression in group 2 were significantly higher than that in group 1.
CONCLUSIONSThe compound Zaofan pill combined with cyclosporine and androgen can obviously increase the levels of MVD and VEGF in bone marrow, and improve the efficacy of treatment in CAA patients.